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Viral infections are one of the major complica­
tions after transplantation. In immunosuppressed 
transplant recipients, morbidity and mortality 
associated with many viral infections increases 
significantly compared with healthy individuals. 
Common viral complications include reactivation 
and resurgence of chronic viruses such as cyto­
megalovirus, Epstein­Barr virus, and polyoma BK 
virus (Fishman and Rubin, 1998; Singh, 2003; 
Fishman, 2007). Severe infections can also arise 
from agents unexpectedly present in the donor   
tissue (Kumar and Humar, 2005; Kotton, 2007). 
This mode of infection, although less common, 
can be associated with severe and fatal conse­
quences and has recently occurred with lympho­
cytic choriomeningitis virus (LCMV) and closely 
related agents in transplant recipients (CDC, 2005, 
2008; Fischer et al., 2006; Palacios et al., 2008).
LCMV infection in humans typically causes 
a subclinical or mild self­limiting febrile disease 
with  some  individuals  experiencing  aseptic 
meningitis (Buchmeier et al., 2007). Although 
infection of human fetus can result in congenital 
abnormalities or death, LCMV disease in healthy 
adults is rarely fatal, with a mortality <1% (Peters,   
2006). However, recently reported cases of LCMV   
infection  in  transplant  recipients  exhibited   
dramatically distinct clinical features from those 
seen in immunocompetent individuals with   
a case mortality rate >90% (CDC, 2005, 2008; 
Fischer  et  al.,  2006;  Palacios  et  al.,  2008).   
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Recently, several cases of fatal lymphocytic choriomeningitis virus (LCMV) infection oc-
curred in transplant recipients being treated with the immunosuppressive calcineurin 
inhibitor FK506. These findings were surprising because LCMV is a noncytolytic virus.  
To understand how a noncytolytic virus can cause disease under conditions of immunosup-
pression, we used the mouse LCMV model and found that, similar to the observations in 
human transplant recipients, LCMV infection of FK506-treated mice resulted in a lethal 
disease characterized by viremia, lack of seroconversion, and minimal lymphocytic  
infiltrates in the tissues. However, despite the apparent absence of an antiviral immune  
response, this disease was orchestrated by virus-specific T cells. FK506 did not prevent the 
generation and proliferation of LCMV-specific T cells but instead altered their differentia-
tion so that these effector T cells lost the ability to control virus but were still capable of 
mediating disease. These pathogenic T cells initiated a cytokine storm characterized by high 
levels of tumor necrosis factor (TNF) and interleukin 6 (IL-6), and depletion of T cells or 
blockade of these inflammatory cytokines prevented the lethal disease. Our study shows 
that inhibiting calcineurin can generate pathogenic T cells and indicates that T cell–mediated 
viral disease can occur even under conditions of immunosuppression. Furthermore,  
we identify a potential strategy (blockade of TNF and IL-6) for treatment of transplant 
recipients who have acute complications of viral infection.
© 2010 Araki et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Oldstone et al., 1977). High mortality caused 
by  LCMV  infection  is  generally  associated 
with  immunopathology  rather  than  direct   
viral damage. Indeed, in contrast to immuno­
suppressed transplant recipients, LCMV­infected 
immune­deficient mice, such as RAG knock­
out,  SCID,  and  nude  mice,  do  not  show   
apparent clinical symptoms despite high levels 
of viremia. Thus, LCMV infection in mice 
causes lethal disease only when virus­specific 
T cells attack critical infected organs (Borrow and Oldstone, 
1997). Similarly, in severe cases of LCMV infection in immuno­
competent humans, meningitis occurs along with increase   
of  lymphocyte  counts  in  cerebrospinal  fluid,  suggesting   
immune­mediated disease (Peters, 2006). Thus, pathogenesis 
of LCMV infection in transplant recipients appears to be quite   
distinct from that seen in immunocompetent humans or 
from the classical observations made in mice (Borrow and   
Oldstone, 1997).
It is important to investigate the mechanism of LCMV 
disease in the presence of the calcineurin inhibitor FK506, the 
most effective and commonly used immunosuppressive drug 
in transplantation, not only for developing potential treatment 
strategies but also for understanding how a noncytolytic virus 
can cause lethal disease under conditions of immunosuppres­
sion. To address this issue, we have used the mouse model of 
LCMV infection to examine how FK506 alters the pathogen­
esis of acute viral infection. We found that, similar to what 
was  seen  in  the  transplant  recipients,  infection  of  FK506­
treated mice with the LCMV Armstrong strain, which nor­
mally causes an acute self­limiting infection in adult mice, 
resulted in a lethal disease characterized by high levels of   
viremia,  lack  of  seroconversion,  and  minimal  lymphocytic   
infiltrates in the tissues. However, we found that despite the 
Overall, 13 patients in four different clusters received allografts 
that were infected with the virus, and all patients developed 
clinical disease with 12 of them dying (CDC, 2005, 2008; 
Fischer et al., 2006; Palacios et al., 2008). These recipients had 
sustained viremia, and virus was also detected in multiple or­
gans as a result of lack of protective immune responses because 
the transplant recipients were under immunosuppressive 
medications (Fischer et al., 2006; CDC, 2008; Palacios et al., 
2008). In addition, only minimal inflammatory infiltrates in 
tissues were observed and there was no seroconversion in 
most of the transplant recipients (Fischer et al., 2006). Based 
on these clinical observations, it was suggested that the lethal 
LCMV disease in these transplant recipients that were under   
a FK506­based immunosuppressive regimen was caused by   
direct viral damage and was not immune mediated (Fischer   
et al., 2006; Peters, 2006).
It is surprising and somewhat paradoxical that LCMV in­
fection in transplant recipients resulted in such high mortality 
without evidence of immunopathology because LCMV is a 
noncytolytic virus and is the classical model of immune­ 
mediated viral disease (Borrow and Oldstone, 1997). The virus 
itself can cause disease by altering the infected cell functions 
without interrupting their vital functions, but the outcome of 
this disease is usually nonlethal (Borrow and Oldstone, 1997; 
Figure 1.  LCMV infection in the presence of 
FK506 results in high mortality. B6 mice were in-
fected with LCMV Armstrong in the presence or absence 
of FK506 treatment. FK506 was injected subcutane-
ously every day into B6 mice from day 1 of infection. 
(A) Survival curve of LCMV Armstrong–infected mice with 
or without FK506 treatment (n = 6, LCMV; n = 12, LCMV + 
FK506). (B) Mean body weight was tracked after infec-
tion (n = 6, LCMV; n = 12, LCMV + FK506). (C) Serum 
viral titers were measured by plaque assay (n = 3, each 
time point). (D) Endpoint titers of anti-LCMV IgG in 
serum were detected by ELISA (n = 3, each time point). 
Error bars for B–D indicate SEM. (E) Aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) in 
serum were analyzed from naive FK506-treated un-
infected, LCMV-infected, and LCMV-infected FK506-
treated mice on days 12–15 after infection or drug 
treatment. Each circle represents individual animals. 
Horizontal bars show the mean. *, P < 0.05; **, P < 0.01. 
The horizontal dashed lines in C and D indicate the 
lower limit of detection. Data (A–E) were pooled from 
two independent experiments.JEM VOL. 207, October 25, 2010 
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hepatitis (Fig. S1 B). 
In  addition,  liver 
enzyme  levels  in   
serum were elevated 
in FK506­treated infected animals (Fig. 1 E). Similar patterns 
of sustained viremia, no seroconversion, along with mild   
lymphocyte infiltration, high morbidity and mortality, and   
elevated levels of liver enzyme in serum were described in 
transplant patients that received LCMV­contaminated organs 
(Fischer et al., 2006).
LCMV-specific CD8+ T cells expand in the presence of FK506 
but do not differentiate into functional effector cells
Experiments in the previous section showed impaired hu­
moral immune responses in FK506­treated LCMV­infected 
animals (Fig. 1 D). Next, to determine whether FK506 in­
hibits cellular immunity, an analysis of the phenotype and 
function of virus­specific CD8+ T cell responses in infected 
control and FK506­treated animals was performed. Surpris­
ingly, a comparison of CD8+ T cell responses measured by 
MHC class I tetramers for the GP33 epitope revealed initially 
similar numbers in both FK506­treated and control animals 
(Fig. 2 A). However, beyond 6 d, the magnitude of GP33­
specific CD8 T cell responses in drug­treated animals was 
significantly lower than in controls (Fig. 2 A). This phenom­
enon was also observed with three other LCMV­specific CD8 
T cell epitopes (Fig. 2 B). By day 15, responses of FK506­treated 
animals were, on average, 10­fold lower in magnitude than 
controls (Fig. 2 A).
These virus­specific CD8+ T cells in both control and 
FK506­treated  animals  showed  an  activated  phenotype 
(CD127Low, CD62LLow, and CD44High) at day 8 after in­
fection (Fig. 3 A). However, there were striking differ­
ences in the function of CD8+ T cells in FK506­treated 
versus control animals. Thus, although almost all of the 
GP33/34­specific CD8+ T cells from untreated controls 
produced IFN­ at day 6 and 50% TNF, markedly fewer 
apparent absence of virus­specific immune responses, this   
lethal LCMV disease in FK506­treated mice was T cell medi­
ated. Surprisingly, the immunosuppressive drug FK506 did 
not prevent the proliferation and generation of LCMV­ 
specific CD8 and CD4 T cells but dramatically altered their 
differentiation so that these effector T cells lost their ability to 
control LCMV infection but were still capable of mediating 
disease. Our studies show that T cell–mediated viral disease 
can occur even in the presence of immunosuppression and 
have important implications for transplantation. These results 
provide a potential new strategy for treatment in transplant 
recipients who have acute complications of viral infection.
RESULTS
A mouse model of LCMV infection in the presence of FK506 
mimics LCMV disease in human transplant recipients
To model LCMV infection of human transplant recipients, 
we used a mouse model of LCMV strain Armstrong infection 
that causes acute systemic infection. This infection is asymp­
tomatic in immunocompetent mice and virus is cleared within 
8 d after infection (Wherry et al., 2003). In this study, groups 
of control and calcineurin inhibitor FK506­treated B6 mice 
were infected with LCMV strain Armstrong. Drug treatment 
was begun 1 d before infection and continued daily. As was 
expected, LCMV infection of control mice gave little or no 
sign of disease and virus was eliminated by day 8 after infec­
tion (Fig. 1, A–C). In contrast, infection of FK506­treated 
mice resulted in clinical signs and significant weight loss start­
ing 7–8 d after infection with >50% of animals dead by 20 d 
after infection (Fig. 1, A and B). Although untreated mice 
controlled infection by day 8, significant viremia remained 
throughout the observation period in drug­treated animals 
and none developed detectable levels of anti­LCMV serum 
antibodies suggesting minimal B cell responses (Fig. 1, C and D). 
Inflammatory infiltrates were mild or unapparent in brains, lungs, 
kidneys, and livers of drug­treated animals (Fig. S1, A and B), 
but a few drug­treated animals did show minimal to mild 
Figure 2.  Kinetics of LCMV-specific CD8 
T cell responses in the presence of FK506. 
B6 mice were infected with LCMV Armstrong 
with or without FK506 treatment. (A) The 
percentage of CD8+ T cells from spleen stain-
ing positive for DbGP33 tetramer is shown for 
a representative mouse on days 6, 8, and 15 
after infection (left). Flow cytometry plots are 
gated on CD8+ T cells and the number indi-
cates the percentage of DbGP33 tetramer+ 
cells. Shown on the right is the mean number 
of CD8+ T cells/spleen specific for the DbGP33 
epitope (n = 3–6, each time point). *, P < 0.01.  
(B) The mean number of CD8+ T cells/spleen 
specific for other three dominant epitopes 
(left, DbNP396; center, DbGP276; right, 
KbGP34) at days 6 and 8 after infection in 
control and FK506-treated mice (n = 3–6, 
each time point). Error bars in A and B indi-
cate SEM. The horizontal dotted lines in  
A and B show the lower limit of detection.  
*, P < 0.05; **, P < 0.01; ***, P < 0.0001. Data 
for A and B are representative of two or  
three independent experiments.2358 Viral disease during immunosuppression | Araki et al.
In  addition  to  defect  of  cytokine  production,  despite 
higher levels of granzyme B expression (Fig. 3 C) and normal 
degranulation ability (Fig. S2 A), a chromium release assay 
showed that cytotoxic activity was impaired in drug­treated 
animals  compared  with  untreated  controls  (Fig.  3  D).   
CD8+ T cells from treated animals were IFN­ and TNF 
producers (Fig. 3 B). Moreover, by day 8, differences be­
tween the two groups were even more evident and cells pro­
ducing both cytokines were virtually absent in FK506­treated 
mice (Fig. 3 B).
Figure 3.  FK506 treatment alters effector CD8 T cell differentiation. B6 mice were infected with LCMV Armstrong with or without FK506 treat-
ment. (A) Phenotype of DbGP33 tetramer+ CD8+ cells was compared between FK506-treated and untreated mice on day 8 after infection. Flow cytometry 
data are gated on DbGP33 tetramer+ CD8+ cells. The gray line shows CD8+ T cells of naive B6 mice. (B) IFN- and TNF production of spleen CD8 T cells stim-
ulated or not with GP33 peptide for 5 h on days 6 and 8 after infection. For better comparison of frequencies of tetramer-positive cells and cytokine- 
producing cells, DbGP33 and KbGP34 tetramer-positive cells were detected together in one flow panel. The flow cytometry plots of each panel are gated on 
CD8+ T cells. (C) Granzyme B expression in DbGP33 tetramer+ CD8+ T cells was examined on day 8 after infection. The gray line shows granzyme B levels in 
CD8+ T cells of a naive mouse. The number represents mean fluorescence intensity of granzyme B in DbGP33+ cells (black histogram). (D) Ex vivo cytotoxic 
activity of spleen cells isolated from FK506-treated or untreated LCMV-infected mice on day 8 after infection was measured in a 5-h chromium release 
assay. Target cells were GP33 peptide-pulsed or unpulsed MC57 cells. The effector/target cell ratios (E:T) of the top two panels show total spleen cells to 
targets. The effector/target cell ratios of the bottom panel were calculated by antigen-specific tetramer-positive cells. Error bars indicate SEM. (E) The ex-
pression of PD-1 on DbGP33 tetramer+ CD8+ cells was compared between spleen cells of FK506-treated and untreated mice on day 8 after infection. As a 
positive control, PD-1 expression after LCMV strain clone 13 infection (day 8 after infection) is shown on the bottom. Flow cytometry data are gated on 
DbGP33 tetramer+ CD8+ cells. The gray line shows CD8+ T cells of naive B6 mice. Data (A–E) are representative of at least two independent experiments.JEM VOL. 207, October 25, 2010 
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It is important to understand the mechanism by which 
FK506 treatment induces the unusual dysfunction of virus­
specific CD8 T cells because CD8 T cells play critical roles in 
both controlling LCMV infection and mediating LCMV dis­
ease. FK506 is well known to suppress activation of calcineu­
rin and, thereby, block its ability to activate NFAT, which 
transcribes specific genes including IFN­. In addition, a re­
cent paper has shown that NFAT also regulates PD­1 expres­
sion on T cells (Oestreich et al., 2008). Thus, FK506 might 
directly inhibit the calcineurin­NFAT signaling pathway in­
trinsic in virus­specific CD8 T cells to alter T cell differ­
entiation.  However,  because  FK506­treated  mice  showed 
significant changes, including clinical manifestation and viral 
titers, this effect could alter T cell function. To address this 
question, we made FK506­insensitive virus­specific CD8   
T cells by knocking down FKBP12 using a retrovirus­based 
short hairpin (sh) RNA system expressing GFP as a transduc­
tion marker. FKBP12 is an essential intracellular binding 
partner of FK506, so that without FKBP12, FK506 is unable 
to inhibit activation of calcineurin. Control or FKBP12 
knockdown retrovirus­transduced LCMV­specific transgenic 
CD8 T cells were adoptively transferred into naive mice, fol­
lowed by LCMV infection in the presence of FK506 (Fig. 4, 
A–C). We were able to determine intrinsic effects of FK506 
in virus­specific CD8 T cells by comparing GFPpositive trans­
duced cells with GFPnegative nontransduced cells (Fig. 4, A and B). 
Using this system, we examined whether PD­1 expression 
and cytokine production were changed in FK506­insensitive 
antigen­specific CD8 T cells. PD­1 expression levels in­
creased  on  antigen­specific  CD8  T  cells  with  FKBP12 
knockdown in FK506­treated mice (Fig. 4 C). Production of 
IFN­ was also enhanced in these FK506­insensitive antigen­
specific CD8 T cells to peptide stimulation (Fig. 4 C).   
Furthermore, we observed modest restoration of TNF pro­
duction by FKBP12 knockdown (Fig. 4 C). These results 
show  that  FK506  acts  intrinsically  in  virus­specific  CD8   
T cells to induce PD­1low functionally impaired T cells.
Next, to investigate differences in kinetics of virus­specific 
CD8+ T cell responses between treated and untreated ani­
mals, we analyzed CD8+ T cell proliferation, phenotype, and 
function at an early time point (day 4) of infection using 
LCMV­specific transgenic CD8+ T cells. CFSE profiles dem­
onstrated that there were minimal differences in the rate of 
the division of antigen­specific T cells in virus­infected drug­
treated versus untreated mice and no significant changes in 
the absolute number of antigen­specific T cells (Fig. 5 A), 
showing that FK506 did not inhibit initial proliferation of   
virus­specific CD8 T cells. However, functional and pheno­
typic differences were already seen at this early time point, 
and LCMV­specific CD8 T cells in drug­treated mice showed 
impaired cytokine production and high levels of granzyme B 
(Fig. 5, B and C). Interestingly, we found striking differe­
nces in the expression of CD27 and the killer cell lectin­like 
receptor G1 (KLRG­1). LCMV­specific transgenic CD8+  
T  cells  of  FK506­treated  mice  expressed  lower  levels   
of CD27 and more KLRG­1 than did cells of control mice 
Such impaired cytotoxic activity in drug­treated mice was also 
observed in an in vivo killing assay (Fig. S2 B). In addition, the 
decreased in vivo killing ability was confirmed on a per cell 
basis in another in vivo killing experiment where the effector/ 
target cell ratio was tightly controlled by adoptive transfer of 
effector CD8 T cells (Fig. S3). Collectively, these data indicate   
that impaired function of cytokine production and cytotoxic 
activity was evident in virus­specific CD8+ T cells in FK506­
treated mice, which likely accounted for the failure of T cells 
from treated animals to control virus infection.
Interestingly, this functional impairment was not associ­
ated with a programmed death 1 (PD­1) expression (Fig. 3 E). 
As shown previously (Barber et al., 2006), this inhibitory re­
ceptor was highly expressed on exhausted virus­specific CD8 
T  cells  in  immunocompetent  mice  infected  with  LCMV 
clone 13 strain that caused chronic infection (Fig. 3 E). How­
ever, virus­specific CD8 T cells in drug­treated LCMV­infected 
animals showed minimal PD­1 expression, similar to untreated 
animals (Fig. 3 E). These data indicate that dysfunction of   
virus­specific CD8 T cells in the presence of FK506 is dis­
tinct from that seen in chronic infection.
Figure 4.  FK506 acts intrinsically in virus-specific CD8 T cells to 
alter T cell differentiation. Thy-1.1+ LCMV-specific P14 transgenic naive 
CD8 T cells were activated in vivo and then transduced with retroviruses 
(marked by GFP expression) expressing shRNA for FKBP12 or empty control 
vector. These transduced P14 cells were then adoptively transferred into 
naive Thy-1.2+ mice and these mice were infected with LCMV in the pres-
ence of FK506. Spleen cells were used for analysis on day 5 after infection. 
(A) Retrovirus-transduced Thy-1.1+ P14 cells were distinguished by GFP 
expression. The dot plots are gated on P14 cells. (B) GFP+ retrovirus- 
transduced P14 cells were purified by FACS, and then FKBP12 expression 
was examined by Western blotting. (C) Phenotypic and functional analysis 
of retrovirus-transduced cells. PD-1 and cytokine expression (IFN- and 
TNF upon peptide stimulation) on retrovirus-transduced (GFP+) and non-
transduced (GFP) P14 cells in spleen cells on day 5 after infection. For 
cytokine expression, spleen cells were stimulated with GP33 peptide for  
5 h. Data are representative of three independent experiments.2360 Viral disease during immunosuppression | Araki et al.
T cells of FK506­treated mice rapidly became terminally   
differentiated effector cells compared with control animals   
(Hamann et al., 1997; Voehringer et al., 2001; Joshi et al., 2007; 
Sarkar et al., 2008). In addition, we found a higher frequency 
(Fig. 5, B and C). This phenotypic feature was also seen on 
endogenous  LCMV­specific  tetramer+  cells  in  LCMV­ 
infected  FK506­treated  B6  mice  (Fig.  S4).  The  CD27Low 
KLRG­1high  phenotype  suggests  that  virus­specific  CD8   
Figure 5.  Virus-specific T cells proliferate but do not accumulate in the presence of FK506. CFSE-labeled P14 transgenic T cells that bear GP33-
specific TCR and Thy-1.1 marker were adoptively transferred into Thy-1.2+ recipient B6 mice 1 d before infection, and then FK506 treatment was started. 
The next day (day 0), these mice were infected or not with LCMV Armstrong, and spleen cells were isolated on day 4 after infection for analysis. (A) Prolif-
eration and the absolute number of P14 cells were assessed in spleen. Histograms were gated on P14 Thy-1.1+ CD8+ transgenic T cells. Horizontal bars 
(right) show the geometric mean. (B and C) Cell surface and functional markers on gated Thy-1.1+ CD8+ P14 cells. For cytokine expression, spleen cells 
were stimulated with GP33 peptide for 5 h. Flow cytometry plots in B are shown as histograms in C. (D) Apoptosis of effector CD8 T cells as determined 
by Annexin V and 7AAD staining. Plots are gated on P14 transgenic T cells. Data (A–D) are representative of two or three independent experiments.JEM VOL. 207, October 25, 2010 
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were absent in FK506­treated mice after pep­
tide stimulation (Fig. 6 C).
Generation of pathogenic T cells in FK506-
treated mice
LCMV  disease  in  immunocompetent  mice  is 
the classical example of T cell–mediated viral 
disease (Borrow and Oldstone, 1997). LCMV­
infected mice develop clinical signs only when 
effector T cells attack virus­infected critical or­
gans. In this circumstance, effector T cells are 
usually functional in terms of cytokine produc­
tion and cytotoxic activity. In contrast, virus­specific T cells 
in the presence of FK506 were dysfunctional. Therefore, it 
was  important  to  investigate  whether  these  dysfunctional   
T cells could mediate lethal disease in LCMV­infected FK506­
treated mice. To address this question, either CD4 or CD8   
T cells were depleted from the mice by injecting anti­CD4 
or ­CD8 antibody on days 0 and 3 after infection. We found 
that depletion of CD8+ cells resulted in fewer FK506­treated 
animals succumbing to infection, whereas CD4+ depletion had 
no effect (Fig. 7 A). However, simultaneous depletion of both 
T cell subsets completely abrogated the adverse effects of im­
munosuppression so that all drug­treated animals survived after 
LCMV infection (Fig. 7 A). Virus was, not surprisingly, de­
tected in all groups (Fig. 7 A). In addition to T cell depletion 
experiments, LCMV­infected RAG/ mice that lacked adap­
tive immunity did not develop disease in the presence of FK506 
(Fig. S5). These data show that T cells were involved in the 
mediation of disease in FK506­treated LCMV­infected mice 
rather than direct viral injury and that the cells involved were 
likely to be principally the CD8+ T cells.
These  experiments  revealed  that  the  consequences  of 
FK506  suppression  impaired  the  protective  function  of   
T cells, but these T cells still retained their ability to cause 
clinical disease. We next examined if inflammatory cytokines 
were involved in this disease. To address this issue, we mea­
sured serum cytokine levels in drug­treated and untreated ani­
mals. FK506­treated animals showed markedly higher serum 
levels of the inflammatory cytokines TNF and IL­6 compared 
with control infected animals (Fig. 7 B). In contrast, another 
inflammatory cytokine IL­17 was not detected in serum of   
of apoptotic cells in LCMV­infected FK506­treated animals 
based on Annexin V and 7­aminoacitinomycin d (7AAD) 
staining (Fig. 5 D). These results account for the observation 
that the overall expansion of virus­specific CD8+ T cells in 
FK506­treated  mice  was  significantly  inhibited  compared 
with controls after day 8, despite the fact that initial prolifera­
tion was similar. Collectively, our results (Figs. 2–5) show 
that the calcineurin inhibitor FK506 does not prevent the 
generation of virus­specific CD8 T cells but dramatically   
alters their differentiation.
FK506 treatment alters virus-specific CD4 T cell responses 
after LCMV infection
We next examined whether FK506 treatment changed CD4 
T cell responses in LCMV­infected mice. Interestingly, in 
FK506­treated mice, the number of CD44high CD4+ T cells 
was higher than control animals on day 6 (Fig. 6 A). As was 
expected from the results of CD8+ T cell responses, the abso­
lute number of antigen­experienced CD4+ T cell responses in 
drug­treated animals was significantly less than in controls   
after day 8 (Fig. 6 A). However, high expression levels of 
granzyme B in CD4+ cells of FK506­treated animals were 
maintained throughout infection (Fig. 6 B). In contrast to 
LCMV­infected  mice,  FK506  treatment  alone  without 
LCMV infection had minimal or no effect on granzyme ex­
pression (unpublished data). Thus, it seems that such higher 
levels of granzyme B expression in drug­treated LCMV­ 
infected mice were induced by continuous TCR stimulation 
by high levels of persistent viral antigen. Similar to what 
was seen in CD8+ T cells, IFN­–producing CD4+ T cells 
Figure 6.  CD4 T cell responses in FK506-treated 
mice. B6 mice were infected with LCMV Armstrong in the 
presence or absence of FK506. (A) The number of CD44High 
CD4+ T cells/spleen is plotted over time after infection. 
Data are the mean for three mice/time point. Error bars 
indicate SEM. *, P < 0.05; **, P < 0.01. (B) The percentage 
of CD44high CD4+ T cells staining positive for granzyme B is 
shown for spleen cells of a representative mouse at each 
time point. (C) IFN- production by CD4+ T cells stimulated 
with LCMV peptide for each group 8 d after infection. 
Spleen cells were stimulated with GP61 peptide (LCMV 
CD4 epitope) or left unstimulated for 5 h. Numbers repre-
sent the percentage of IFN-+ cells in CD4 T+ cells. Data 
(A–C) are representative of two independent experiments.2362 Viral disease during immunosuppression | Araki et al.
mice adoptively transferred with P14 cells (Fig. 8 D). These 
data indicate that functionally impaired virus­specific T cells 
orchestrate LCMV lethal disease in FK506­treated animals and 
induce overproduction of inflammatory cytokines.
Liver macrophages produce inflammatory cytokines  
in LCMV-infected FK506-treated mice
Virus­specific T cell–dependent inflammatory cytokine pro­
duction in FK506­treated mice is somewhat paradoxical be­
cause virus­specific T cells generated in the presence of this 
drug do not substantially produce TNF (Fig. 3 B). In addition, 
virus­specific CD8 T cells were unable to produce IL­6 either 
in the presence or absence of FK506 (unpublished data). Thus, 
these  data  suggest  that  functionally  impaired  virus­specific   
T cells orchestrate the production of inflammatory cytokines, 
but they do not themselves produce these cytokines. Indeed, 
in FK506­treated mice, we found high levels of inflammatory 
cytokines as well as the accumulation of macrophages in livers 
(Fig. 9) in which mild hepatitis was observed (Fig. 1 E and 
Fig.  S1  B).  Thus,  liver  homogenates  of  FK506­treated   
mice had higher levels of TNF and IL­6 than control animals 
(Fig.  9  A),  and  fivefold  higher  numbers  of  macrophages 
(CD11b+ F4/80+) were recovered from the livers of infected 
FK506­treated animals (Fig. 9, B and C). Furthermore, accu­
mulated macrophage populations in FK506­treated mice had 
higher TNF and IL­6 mRNA levels than control mice (Fig. 9 D). 
either control or drug­treated mice (<2.4 pg/ml). High levels 
of TNF and IL­6 were evident in the late phase when treated 
mice were showing clinical disease. In addition, mice depleted 
of CD4 and CD8 T cells in which the pattern of disease was 
fully reversed showed lower levels of TNF and IL­6 com­
pared with undepleted FK506­treated mice (Fig. 7 B).
However, because T cell­depletion by antibodies removes 
all T cells, including virus­specific and naive CD4/8 T cells, 
and T reg cells, it is unclear if the disease manifestation and 
overproduction of inflammatory cytokines was directly medi­
ated by virus­specific T cells. To investigate this issue, we adop­
tively transferred either LCMV­nonspecific (OT­1) or ­specific 
(P14) transgenic CD8 T cells into RAG/ mice, followed by 
LCMV infection in the presence or absence of FK506 treat­
ment (Fig. 8). Our data clearly showed that LCMV disease was 
mediated by virus­specific T cells in FK506­treated animals. 
Thus, only mice that received LCMV­specific P14 cells com­
bined with FK506 treatment succumbed to infection, and all 
other groups (OT­1 with or without FK506 and P14 without 
FK506) survived (Fig. 8 A). Virus was controlled only in a 
group that received LCMV­specific P14 cells without FK506 
treatment (Fig. 8 B). In addition, in the presence of FK506, P14 
transgenic T cells lost their ability to produce IFN­ and TNF, 
similar to wild­type B6 mice (Fig. 8 C). Furthermore, similar 
patterns of high levels of the inflammatory cytokines TNF and 
IL­6 were observed in LCMV­infected FK506­treated RAG/ 
Figure 7.  Pathogenic T cells orchestrate inflammatory cytokine production. B6 mice were infected with LCMV Armstrong in the presence or ab-
sence of FK506. (A) For single depletion of CD4+ and CD8+ T cells, either anti-CD4 or anti-CD8 antibody was injected i.p. into LCMV-infected B6 mice on 
day 0 and day 3 of infection. For double depletion of CD4+ and CD8+ T cells, both anti-CD4 and -CD8 antibodies were injected. Survival curves are shown 
on the left (n = 21, LCMV + FK506; n = 13, LCMV + FK506 + CD4 depletion; n = 17, LCMV + FK506 + CD8 depletion; n = 9, LCMV + FK506 + double de-
pletion). *, P < 0.05 (vs. LCMV + FK506). For viral titer, sera were collected at three different time points (days 6, 12–15, and 30 after infection). The mean 
viral titer in serum is shown (n = 3–9, each time point). (B) Serum cytokine levels were measured using cytometric bead array (n = 3–9, each time point). 
The horizontal dashed lines indicate the lower limit of detection. There were no detectable levels of IFN-, TNF, and IL-6 in serum of uninfected mice 
treated with FK506 for 15 d (not depicted). Error bars in A and B indicate SEM. Data for A and B were pooled from two or three independent experiments.JEM VOL. 207, October 25, 2010 
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DISCUSSION
Immunosuppressed  transplant  patients  that   
inadvertently contracted LCMV infection from 
their  organ  allograft  showed  high  mortality, 
and most of the clinical information obtained 
from the transplant patients that were under an 
FK506­based regimen suggested that the patho­
genesis of LCMV disease was direct viral injury 
and not immune mediated (Fischer et al., 2006; 
Peters,  2006).  However,  such  high  mortality 
without evidence of immunopathology was   
unexpected  because  LCMV  is  a  noncytolytic   
virus, and disease is usually associated with tissue damage 
when  immunopathologic  T  cells  destroy  viral­infected 
cells in critical organs (Borrow and Oldstone, 1997). In this 
study, we investigated how the calcineurin inhibitor FK506 
changed viral disease manifestation and virus­specific T cell 
responses  after  LCMV  infection  using  a  mouse  model. 
FK506­treated LCMV­infected mice showed high lethality 
and, importantly, this mouse model mimicked LCMV disease 
seen in the transplant recipients.
We defined two critical stages to develop the lethal disease in 
LCMV­infected mice in the presence of FK506. A first stage is 
generation of pathogenic T cells that were not protective but 
mediated clinical disease. Therefore, when this stage was blocked 
by T cell depletion, the pattern of the disease was fully reversed 
and all animals survived. A second critical stage is overproduc­
tion of inflammatory cytokines principally involving TNF and 
IL­6. In drug­treated infected animals, overproduction of these 
cytokines was coincident with the development of disease and 
death. Inhibiting these cytokines in drug­treated animals also re­
versed the disease phenotype. Thus, TNF and IL­6 are major 
players  for  disease  manifestation  in  LCMV­infected  FK506­
treated mice. More importantly, such inflammatory cytokine pro­
duction was orchestrated by functionally impaired virus­specific 
Our results suggest that functionally impaired virus­specific   
T cells induce the production of inflammatory cytokines by 
other cells such as liver macrophages.
Overproduction of inflammatory cytokines responsible  
for lethal disease in LCMV-infected FK506-treated mice
The data in the previous section suggest that clinical disease 
was a result of the pathogenic effects of high cytokine levels of 
TNF and IL­6 because overproduction of inflammatory cyto­
kines was only seen in the mice with severe clinical signs. This 
was tested by experiments in which groups of FK506­treated 
LCMV­infected mice were given inhibitors of TNF and IL­6 
and the outcome was compared. As the data in Fig. 10 show, 
although anti–IL­6 receptor antibody had no statistically sig­
nificant impact on survival, treatment with soluble TNF re­
ceptor,  which  is  an  inhibitor  of  TNF,  led  to  a  significant 
improvement  in  survival.  More  significantly,  simultaneous 
blockade of TNF and IL­6 provided the greatest protection, 
with >90% of mice surviving for the duration of the experi­
ment. These results show that LCMV­infected FK506­treated 
animals were dying because of an excessive inflammatory   
cytokine response that was orchestrated by pathogenic virus­
specific T cells generated in the presence of FK506.
Figure 8.  Functionally impaired virus-specific  
T cells mediate LCMV lethal disease in FK506-treated 
mice. Purified P14 (LCMV specific) or OT-1 (nonspecific) 
transgenic CD8 T cells were adoptively transferred into 
RAG1/ mice, followed by LCMV infection in the pres-
ence or absence of FK506. (A) Survival curve (n = 6, LCMV + 
OT-1; n = 6, LCMV + OT-1 + FK506; n = 11, LCMV +  
P14; n = 12, LCMV + P14 + FK506). (B) Serum viral titers 
(n = 5–6 in each group, day 9 after infection). The hori-
zontal dashed line indicates the lower limit of detection. 
(C) IFN- and TNF production by P14 cell transfer is 
shown on day 7 after infection for a representative 
mouse from two independent experiments. Spleen cells 
were stimulated or not with GP33 peptide for 5 h. The 
flow cytometry plots of each panel are gated on P14 cells. 
(D) Serum cytokine levels on day 9 after infection for each 
of the four groups were measured using cytometric bead 
array (n = 5–6, each group). *, P < 0.05; **, P < 0.01. Error 
bars in B and D indicate SEM. Data (A, B, and D) were 
pooled from two independent experiments.2364 Viral disease during immunosuppression | Araki et al.
CD8  T  cells  generated  in  FK506­treated  LCMV­infected   
animals had higher levels of granzyme B than control animals 
(Fig. 3 C). Such increase of granzyme B expression in the pres­
ence of FK506 was not seen in NK cells (unpublished data). 
Also, FK506 treatment itself without LCMV infection did not 
induce granzyme B in T cells (unpublished data). Because ex­
pression levels of granzyme B in T cells correlate with TCR 
stimulation, the increase of granzyme B expression in antigen­
specific CD8 T cells in the drug­treated LCMV­infected mice is 
likely a result of continuous TCR stimulation by high levels of 
persistent viral antigen. In addition, degranulation ability was 
maintained in these functionally impaired T cells (Fig. S2 A). 
These observations suggest that virus­specific CD8 T cells gen­
erated in the presence of FK506 still retain some functionality to 
respond to viral antigen, and they might be able to kill infected 
target cells. Indeed, although killing activity was below the de­
tectable levels by a chromium release assay in FK506­treated 
LCMV­infected mice, we observed low levels of killing activity 
of these cells in vivo using a highly sensitive in vivo killing assay 
(Fig. S2 B and Fig. S3). This retained ability of the functionally 
impaired T cells is too weak to eliminate LCMV, but this might 
cause activation of macrophages by damaging infected cells or 
directly responding to infected macrophages.
In  addition  to  the  pathogenic  effect  of  antigen­specific 
CD8 T cells, it was surprising that virus­specific T cells prolif­
erated when the daily administration of FK506 was started 1 d 
before infection because FK506 is one of the most effective 
immunosuppressive drugs. Even when the FK506 treatment 
was begun 3 d before infection, significant levels of initial   
T cells generated during the first stage. Therefore, mice lacking 
these pathogenic T cells in the presence of FK506 had reduced 
levels of the inflammatory cytokines in serum.
We also found that the pathogenic T cells themselves were 
not the major producers of the inflammatory cytokines and that 
liver macrophages could be a significant source of these cyto­
kines  in  LCMV­infected  FK506­treated  mice.  How  do  the 
functionally impaired pathogenic T cells stimulate macrophages 
to produce these inflammatory cytokines? It is well understood 
that macrophage activation is induced by IFN­ derived from 
effector T cells. The pathogenic T cells do not produce substan­
tial IFN­ but very low levels of IFN­ might activate macro­
phages. Furthermore, although these pathogenic T cells were 
functionally impaired, these virus­specific CD8 T cells in 
FK506­treated LCMV­infected mice did not entirely loose their 
ability to respond to viral antigen. Specifically, the virus­specific 
Figure 9.  Liver macrophages produce inflammatory cytokines in 
LCMV-infected FK506-treated mice. Liver cytokine levels and intra-
hepatic mononuclear cells were examined 15 d after LCMV infection in the 
presence or absence of FK506. (A) Inflammatory cytokine expression in 
the liver, quantified by cytometric bead array in liver homogenates (n = 6, 
each group). The horizontal dashed lines indicate the lower limit of detec-
tion. (B) Flow plots show CD11b and CD3 staining patterns in intrahepatic 
mononuclear cells (top) and F4/80 staining in CD11b+ CD3 cells (bottom). 
(C) Accumulation of CD11b+ CD3 cells in the liver of FK506-treated mice 
(n = 6, each group). (D) Quantitative RT-PCR analysis of inflammatory 
cytokine expression in CD11b+ cells (n = 3, each group). *, P < 0.05;  
**, P < 0.01; ***, P < 0.001. Error bars in A, C, and D indicate SEM. Data (A–D) 
are representative of two or three independent experiments.
Figure 10.  Overproduction of inflammatory cytokines responsible 
for lethal disease in LCMV-infected FK506-treated mice. B6 mice 
were infected with LCMV Armstrong in the presence or absence of FK506. 
Mice were treated with soluble TNF receptor (sTNFR), which is an inhibitor 
of TNF and/or anti–IL-6 receptor antibody (±IL6R), from day 4 after infec-
tion. Survival curve is shown (n = 12, all groups). *, P < 0.01; **, P < 0.0001. 
Data were pooled from two or three independent experiments.JEM VOL. 207, October 25, 2010 
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distinct virus­specific CD8 T cells from those generated during 
either acute or chronic viral infections.
Such functional impairment and altered differentiation of 
antigen­specific CD8 T cells were reversible when FK506 treat­
ment was stopped. Although stopping the drug treatment at day 
7 after infection did not reduce mortality (Fig. S8 A), it signifi­
cantly decreased viral titers (Fig. S8 B). This better viral control 
was most likely a result of restoration of survival and function   
of antigen­specific T cells. Thus, although deletion of antigen­
specific CD8 T cells occurred by continuous FK506 treatment, 
the discontinuation of the drug improved survival of antigen­
specific CD8 T cells (Fig. S8 C). Furthermore, IFN­ produc­
tion was restored in the group (Fig. S8 D). Therefore, it seems 
that continuous FK506 treatment has a critical role in inducing 
functional impairment and changing T cell differentiation.
In contrast to the effect of FK506, we and others have re­
cently reported that another common immunosuppressive 
drug, rapamycin, has a very different effect on memory T cell 
differentiation (Araki et al., 2009; Pearce et al., 2009). Rapa­
mycin is structurally similar to FK506, and both drugs bind to 
the same intracellular binding partner, FKBP12. However, the 
mechanism of action of these two drugs is different. The 
FK506–FKBP12 complex inhibits the calcineurin–NFAT sig­
naling pathway that initiates activation of specific genes, in­
cluding IL­2, whereas the rapamycin–FKBP12 complex 
prevents mammalian target of rapamycin (mTOR) pathway, 
which  regulates  cell  growth  and  metabolism  (Wullschleger   
et al., 2006). Unlike FK506 treatment, we did not observe ap­
parent clinical symptoms or dysfunctional T cells in LCMV­
infected  mice  treated  with  rapamycin  (Araki  et  al.,  2009).   
In fact, rapamycin treatment enhanced the generation of 
KLRG­1low CD27hi effector T cells and made a higher number 
of memory T cells by improving effector T cell survival (Araki 
et al., 2009). This rapamycin effect on T cell responses was dia­
metrically opposed to the effect of FK506 in LCMV­infected 
mice because FK506 treatment accelerated generation of ter­
minally differentiated end­stage effector cells that eventually 
died  without  differentiating  into  memory  T  cells.  Because 
both calcineurin–NFAT and mTOR pathways become active 
during T cell expansion phase, the balance of these pathways 
might have a critical role in functional effector and memory   
T cell differentiation.
The mechanism of viral disease under the condition of 
calcineurin inhibitor­induced immunosuppression might   
account for pathogenesis in the immunosuppressed LCMV­
infected transplant patients (CDC, 2005, 2008; Fischer et al., 
2006; Palacios et al., 2008). Our mouse model had several 
similarities to the LCMV­infected transplant patients includ­
ing sustained viremia, no seroconversion, along with mild 
lymphocyte infiltration, high morbidity and mortality, and   
elevated levels of liver enzymes in serum (Fischer et al., 2006). 
We suspect that the LCMV­infected transplant patients had 
similar immune­mediated pathological reactions to those seen 
in FK506­treated LCMV­infected mice. Thus, it will be of 
interest to investigate T cell responses and serum inflamma­
tory cytokine levels in LCMV­infected transplant recipients.
T  cell  proliferation  were  seen  in  FK506­treated  animals   
(Fig. S6). These observations were unexpected because calci­
neurin inhibitor is considered to prevent T cell proliferation by 
suppressing IL­2 production, at least in vitro. However, T cell 
proliferation in vivo in the presence of the calcineurin inhibi­
tor is consistent with the observation that IL­2 has minimal   
effects for CD8 T cell expansion after viral infection in vivo 
(Williams et al., 2006). This indicates that CD8 T cells could 
proliferate without IL­2 signals. In addition, LCMV infection 
induces strong innate immune response, including type I IFN, 
that acts directly on CD8 T cells and allows clonal expansion 
(Kolumam et al., 2005). Furthermore, we found that FK506­
treated mice had slightly lower numbers of T reg cells com­
pared with controls, perhaps as a result of decreased expression 
of CD25 (Fig. S7, A and B). CD25 is an essential molecule to 
maintain the number of T reg cells, and to up­regulate CD25 
on T reg cells Foxp3 needs to make a transcriptional complex 
with NFAT in the nucleus (Wu et al., 2006). Because FK506 
blocks translocation of NFAT from the cytoplasm to the nu­
cleus, this may result in reduced CD25 levels and a reduction 
in the number of T reg cells. Accordingly, virus­specific T cells 
might proliferate by such alternative mechanisms (stimulation 
with type I IFN and decreased numbers of T reg cells).
Similar observations about T cell proliferation were shown 
in  previous  studies  in  which  another  calcineurin  inhibitor,   
cyclosporin A, failed to inhibit T cell proliferation in response 
to alloantigens in vivo (Chisholm et al., 1985; Kroczek et al., 
1987). These data suggest that inhibition of T cell proliferation 
might not be a primary role of calcineurin inhibitor in vivo. 
Indeed, we found that virus­specific CD8+ T cells in FK506­
treated animals rapidly differentiated into terminally differenti­
ated end­stage effector cells, compared with controls, and 
showed higher frequency of apoptotic cells. In addition, more 
notable differences of T cells between the drug­treated and 
control­infected  mice  were  detected  by  functional  assays. 
Thus, both CD4+ and CD8+ T cells in FK506­treated animals 
showed increases in granzyme B levels and, perhaps of more 
importance, CD8+ T cells from treated animals showed im­
paired cytotoxic function and did not generate substantial 
IFN­ and TNF in response to antigen stimulation. This pat­
tern of impaired function resembled that of exhausted T cells 
in chronic infection (Zajac et al., 1998; Wherry et al., 2003). 
However, FK506 treatment suppressed expression of the in­
hibitory molecule PD­1, which is an essential molecule for   
T cell exhaustion in chronic infection (Barber et al., 2006; Day 
et al., 2006; Petrovas et al., 2006; Trautmann et al., 2006; 
Radziewicz et al., 2007), suggesting that functional impair­
ment in FK506­treated animals is a PD­1–independent phe­
nomenon.  This  indicates  that  functional  impairment  in 
FK506­treated animals is caused by a different mechanism than 
that which occurs in chronic infection. In support of this no­
tion, we found that the dysfunction of virus­specific CD8   
T cells in FK506­treated mice could be caused by blocking   
the calcineurin–NFAT signaling pathway that is intrinsic in   
T cells. Overall, our data indicate that the calcineurin inhibitor 
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suspensions of spleen cells were prepared, and direct ex vivo staining, in vitro 
peptide stimulation, and chromium release cytotoxic assay were performed 
as described previously (Wherry et al., 2003). For analysis of direct ex vivo 
apoptosis, splenocytes were isolated and incubated with Annexin V and 
7AAD as previously described (Grayson et al., 2002).
ELISA. Anti­LCMV IgG was detected by ELISA, as previously described 
(Ahmed et al., 1984). In brief, 96­well flat­bottom plates were coated with 
LCMV­infected BHK cell lysate, and then each well was blocked by 3% bo­
vine serum albumin PBS. After blocking, serial diluted serum was added, and 
then anti–mouse IgG ( chain specific) conjugated with alkaline phosphatase 
(Sigma­Aldrich) was used as a secondary antibody. p­nitrophenyl phosphate 
(Sigma­Aldrich) was used as substrate.
Retrovirus-based  RNA  interference.  RNA  interference  knockdown 
experiments were performed using pMKO.1 GFP retrovirus vector (pro­
vided by W. Hahn, Harvard Medical School, Boston, MA; Addgene plasmid 
10676) as described previously (Araki et al., 2009). In brief, to activate P14 
cells in vivo, P14 transgenic mice were infected with LCMV Armstrong in­
travenously (2 × 106 PFU). 24 h later, P14 transgenic spleen cells were iso­
lated and then spin transduced with retrovirus. 5 × 105 retroviral­transduced 
P14 spleen cells were adoptively transferred into naive mice, followed by 
LCMV infection (2 × 105 PFU, i.p.).
Quantitative real-time RT-PCR. PCR primers for TNF, IL­6, and ­actin 
were purchased from QIAGEN (QuantiTect Primer). RNA isolation and   
reverse transcription reaction was performed using the RNeasy kit and Quanti­
Tect reverse transcription kit (QIAGEN). For real­time PCR, 2× Quanti­
Tect SYBR Green PCR Master Mix was used as per the manufacturer’s 
instruction (QIAGEN). ­Actin gene expression was used as a reference.
Statistical analysis. Statistical analysis was performed using a two­tailed 
unpaired Student’s t test except for survival experiments. The log­rank test 
was used to determine statistical significance of survival experiments.
Online supplemental material. Fig. S1 shows histopathology in LCMV­
infected FK506­treated mice. Fig. S2 shows degranulation ability and in vivo   
killing activity of virus­specific CD8 T cells in FK506­treated LCMV­ 
infected mice. Fig. S3 shows in vivo killing activity of virus­specific CD8   
T cells in FK506­treated LCMV­infected mice in adoptive transfer experi­
ments. Fig. S4 shows KLRG­1 and CD27 expression on endogenous antigen­
specific CD8 T cells in LCMV­infected FK506­treated mice. Fig. S5 shows 
survival rate and viral titers in LCMV­infected FK506­treated RAG1/ 
mice. Fig. S6 shows virus­specific CD8 T cell expansion in LCMV­infected 
mice treated with FK506 3 d before infection. Fig. S7 shows expression of 
CD25 on regulatory T cells in LCMV­infected FK506­treated mice. Fig. S8 
shows functionality of antigen­specific T cells when FK506 treatment was 
stopped on day 7 after LCMV infection. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20100124/DC1.
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